Recro Pharma (NASDAQ:REPH) Receiving Somewhat Favorable News Coverage, Study Finds

News headlines about Recro Pharma (NASDAQ:REPH) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Recro Pharma earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.0605851947031 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

REPH has been the subject of several recent research reports. Oppenheimer set a $19.00 price objective on Recro Pharma and gave the company a “buy” rating in a research report on Wednesday, February 28th. ValuEngine upgraded Recro Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, March 21st. UBS initiated coverage on Recro Pharma in a research report on Tuesday, February 13th. They issued an “outperform” rating for the company. Finally, CIBC initiated coverage on Recro Pharma in a research report on Wednesday, February 14th. They issued an “outperform” rating and a $19.00 price objective for the company. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $14.21.

REPH opened at $10.58 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.55 and a current ratio of 1.75. Recro Pharma has a 52-week low of $5.81 and a 52-week high of $12.23. The company has a market cap of $208.05, a PE ratio of -5.32 and a beta of -0.74.

Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.22. The company had revenue of $19.04 million for the quarter, compared to analysts’ expectations of $12.88 million. Recro Pharma had a negative return on equity of 75.97% and a negative net margin of 69.61%. equities analysts anticipate that Recro Pharma will post -3.02 EPS for the current year.

In related news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $10.07, for a total value of $2,014,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 21.60% of the stock is owned by corporate insiders.

WARNING: This story was published by BBNS and is owned by of BBNS. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://baseballnewssource.com/2018/04/06/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-recro-pharma-reph-share-price/2029543.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Mets Leave Runner Stranded After Batting Out of Order
Mets Leave Runner Stranded After Batting Out of Order


Leave a Reply

 
© 2006-2018 BBNS.